Radiation Oncology

Mina Fam, MD, discussed his use of MRI and genomic testing to inform his use of HIFU focal therapies vs more radical alternatives.

According to the phase 3 TORPEdO investigators, where IMPT is not used routinely for OPSCC, IMRT remains the standard of care.

Most treatment-related adverse effects were grades 1 or 2, and no grade 4 adverse effects or treatment-related deaths were observed with Lu-PSMA-617.

Mina Fam, MD, explored the integration of multiparametric MRI and genomics in focal HIFU selection and compared its AE profile to radical intervention.

Poster presentations at ELCC 2026 highlighted potential advances in neoadjuvant immunotherapy, intratumoral radioenhancers, and other modalities.

Experts discuss the evolution of rectal cancer care from the use of “cookie cutter” approaches to the growth of personalized treatment pathways.

Low-grade toxicity related to durvalumab in the ASTEROID trial was common, which mostly consisted of skin reactions, pruritus, and fatigue.

Looking ahead, local therapies and biomarkers may become even more important in the management of kidney cancer.

The future of radiation oncology will be largely affected by artificial intelligence and genomics, according to Sheila D. Rege, MD, FACRO.

Bridget Koontz, MD, discussed evaluating the role of concurrent hormone therapy and brachytherapy for prostate cancer that she presented at ASCO GU.

Host Brandon Mancini, MD, MBA, FACRO, discusses presentations from ASCO GU 2026 featuring potential advances in the use of radiotherapeutic regimens.

Tousimis explored the feasibility, complications, and surgical strategies for nipple-sparing mastectomy in patients with a history of radiation therapy.

SkinCure Oncology filed a federal lawsuit against CMS and HHS to challenge the elimination of reimbursement for image-guided radiation therapy for nonmelanoma skin cancer.

A total of 46.6% of patients showed a favorable response to ultrahypofractionation radiotherapy for locally advanced breast cancer.

CAR T-cell therapies and T-cell engagers may produce an “exciting” benefit on the radiosensitization of prostate tumors.

The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.

The expansion of clinical trials evaluating proton-based radiotherapy could elucidate its benefits and increase its access across the US.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Jason Molitoris, MD, PhD, discussed 2025 data on proton therapy for oropharyngeal cancer, highlighting immune preservation and reduced long-term AEs.

According to Charlotte Rivers, MD, it’s important for patients with CNS cancers to meet with all involved doctors so they can make an informed decision regarding their care.

J. Isabelle Choi, MD, shared her specific fractionation preferences and prophylactic strategies to combat adverse effects associated with radiation.

Charlotte Ivy Rivers, MD, explored the impact of updated WHO criteria and functional imaging, such as DOTATATE-PET, on the diagnosis and treatment of patients with CNS tumors.

Sunil W. Dutta, MD, discussed why clinical follow-up remains an essential soft skill for radiation oncologists in an increasingly automated field.